Login / Signup

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.

Renata VaraljaiLisa ZimmerYahya Al-MataryPaulien KapteinLea J AlbrechtBatool ShannanJan C BraseDaniel GusenleitnerTeresa AmaralNina WyssJochen UtikalLukas FlatzFlorian RambowHans Christian ReinhardtJenny DickDaniel R EngelSusanne HornSelma UgurelWiebke SondermannElisabeth LivingstoneAntje SuckerAnnette PaschenFang ZhaoJan M PlackeJasmin M KloseWolfgang P FendlerDaniela S ThommenIris HelfrichDirk SchadendorfAlexander Roesch
Published in: Nature cancer (2023)
Recent studies suggest that BRAF V600 -mutated melanomas in particular respond to dual anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) immune checkpoint inhibition (ICI). Here we identified an over-representation of interleukin (IL)-17-type 17 helper T (T H 17) gene expression signatures (GES) in BRAF V600 -mutated tumors. Moreover, high baseline IL-17 GES consistently predicted clinical responses in dual-ICI-treated patient cohorts but not in mono anti-CTLA-4 or anti-PD-1 ICI cohorts. High IL-17 GES corresponded to tumor infiltration with T cells and neutrophils. Accordingly, high neutrophil infiltration correlated with clinical response specifically to dual ICI, and tumor-associated neutrophils also showed strong IL-17-T H 17 pathway activity and T cell activation capacity. Both the blockade of IL-17A and the depletion of neutrophils impaired dual-ICI response and decreased T cell activation. Finally, high IL-17A levels in the blood of patients with melanoma indicated a higher global T H 17 cytokine profile preceding clinical response to dual ICI but not to anti-PD-1 monotherapy, suggesting a future role as a biomarker for patient stratification.
Keyphrases
  • gene expression
  • case report
  • dna damage
  • clinical trial
  • cell cycle
  • wild type
  • randomized controlled trial
  • dendritic cells
  • small molecule
  • study protocol
  • combination therapy
  • amino acid